{"name":"Y-mAbs Therapeutics","slug":"y-mabs-therapeutics","ticker":"","exchange":"","domain":"","description":"Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer. The company's pipeline includes a diverse range of candidates targeting various oncological indications, with a strong emphasis on innovative bispecific antibodies and radioimmunotherapies.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":87685000,"revenueGrowth":3.4,"grossMargin":0,"rdSpend":48990000,"netIncome":-29666000,"cash":119904000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2020-01-01","label":"Hu3F8 first approved","drug":"Hu3F8","drugSlug":"naxitamab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-01","label":"Hu3F8 PHASE1,PHASE2 readout","drug":"Hu3F8","drugSlug":"naxitamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-04-01","label":"Hu3F8 PHASE2 readout","drug":"Hu3F8","drugSlug":"naxitamab","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"DANYELZA","genericName":"NAXITAMAB-GQGK","slug":"naxitamab-gqgk","indication":"Neuroblastoma","status":"marketed"},{"name":"Hu3F8","genericName":"NAXITAMAB","slug":"naxitamab","indication":"Relapsed or Refractory High-Risk Neuroblastoma","status":"marketed"}]}],"pipeline":[{"name":"DANYELZA","genericName":"NAXITAMAB-GQGK","slug":"naxitamab-gqgk","phase":"marketed","mechanism":"Naxitamab-gqgk binds to GD2 on neuroblastoma cells, inducing CDC and ADCC.","indications":["Neuroblastoma"],"catalyst":""},{"name":"Hu3F8","genericName":"NAXITAMAB","slug":"naxitamab","phase":"marketed","mechanism":"Hu3F8 works by binding to a specific glycolipid on cancer cells, marking them for destruction by the immune system.","indications":["Relapsed or Refractory High-Risk Neuroblastoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNZUF1QUp5V1BjT0I5LV9vUG9VS2paaUhrdUYtcVB0R29lWHlXbThUam5pVUgtcnJnZFdaSTRpTHNDWklLQ2ZPUGZqbUhQQUZaUEJkMEFIanlpN0t5SXdDX1ZHYnRYQ2FWUGJGZzdPRFRraEZHTlVRUDhFbHc3WnNuTEdqZ3ZhT3JtQ1NIbUFhOW1uM2tYMjRHX2VseEhUQnotTkVfcEtLRmVJVUVUSGtxdTl0a1pzNGxLMm9PdnhDN0J2ZS1GLVE?oc=5","date":"2026-03-20","type":"pipeline","source":"AD HOC NEWS","summary":"Y-mAbs Therapeutics stock: Former CEO joins radiopharma board amid biotech sector shifts - AD HOC NEWS","headline":"Y-mAbs Therapeutics stock: Former CEO joins radiopharma board amid biotech sector shifts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTFB2bUZ1VG94SXlPQnEzMm10dWxGV2t0S3pCSmRITk9aVDZHTTlJWTNUSTRkQkFoMXBSSUF1TjJJcG5WMHplVEpJdHhCYUNoTUt3aVhMdmRWdmxwN21IeXk3T3dKbFA?oc=5","date":"2025-12-01","type":"pipeline","source":"PharmaTimes","summary":"Dr Vignesh Rajah - PharmaTimes","headline":"Dr Vignesh Rajah","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPM2ZTTHRYN201bjNKNkptLUtOSmpmV2o1ZlczcE91LW5FSktjTTJmNFZWVmU1YlRWREZweHE2Z0xhREtObjZrZl82VWtPTmJRMnB4aUhSTU1Ya2s4Mjg5Unh3RjV4NG53VWhjYVNaZkRHYWRhcmYteHF6blRtV0NBWmRjcHh0Q2ZBUGcyTjlRR1JUYkVyaVNmaTZIMmlVUHFzbGVIWTNxNjJnNTZkZVZfcnFwZU0xYmlBeDgwTFN4Ml9ScGdQd3lvWTQ0TEtrd181YW9Tc2hnajYtSHJfSHRKX3paTXlIMGNX?oc=5","date":"2025-09-17","type":"deal","source":"Wilson Sonsini","summary":"Firm Advises Centerview Partners as Financial Advisor to Y-mAbs Therapeutics in Acquisition by SERB Pharmaceuticals - Wilson Sonsini","headline":"Firm Advises Centerview Partners as Financial Advisor to Y-mAbs Therapeutics in Acquisition by SERB Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOSHF0UVNzeHIwN1E4SVFvZEJnRUZqNTluUTAyb29aM1NNdnplYjN3cGxienBmMlRFREZ1RDF0Nm1FMVV6Tnh6R0NaODJqNGczc3ZMMGJ5RWczY2VmX05pVXRpNi15cno2TDJhZnVub0xRZnFQaEcwZzE5WTFONVUtVi1zbDdJNkYxeGRBVjY5WmdzSzhyUnpmZUVZUUQ1UUtfNHE0NlBwNzI0Nnd0Z2lHSmE5QkI1dnhodWZpUXhOSjhwZFMxYkxCSGVhc25Xdkg4ZFI4?oc=5","date":"2025-09-16","type":"pipeline","source":"GlobeNewswire","summary":"SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics - GlobeNewswire","headline":"SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOVC1vN2lnQlBDZGFzM21ELVlNa04xMGVxc09ic0NJeEJqQzd5cEhVMlAwejVUVXFSWGtnM0NsR25HQ3h2SENRaGFubmNzMmF6TnI4cWZYaHNFckFzQ3J6Wm1kbHgwUXRTUjFBRzZMX3FVNkJzVFV3S3BBMW92YXpaWkNVdlM3TUUyb1Rucw?oc=5","date":"2025-08-12","type":"deal","source":"Yahoo Finance","summary":"Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock - Yahoo Finance","headline":"Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOR08wSHppb2RTNVcydkZrQXhxMU5ISEdaNXBLWXYwVzZmc0FMRG4xbXllekktcmk4S0k0OFlCbDNXWGQwMS0tcmtzS3VwVGk0cW5nNXZsNnVCS1dnSkgwSi1RZWxrNDFkc0ZEQ2c5OHhSSHo2YW90cFA5blhGMWY4eEdwWU14WE9pNFMzcFFaTlBUZzhXeHQ2UEhaVFJQZ180T0FLYjlVRGIwNGpqSVdPLU5mYVU2Q3YyTmFHR1dUV1Nib09IMkxuR1dHdDE1aXBqeElBVGFCcjVteG1NLTZIZjBUcEZuRVV2VmRlcDRPSQ?oc=5","date":"2025-08-07","type":"pipeline","source":"Mayer Brown","summary":"Mayer Brown advises the group Serb Pharmaceuticals on the structuring of the take-private of Y-mAb Therapeutics Inc. - Mayer Brown","headline":"Mayer Brown advises the group Serb Pharmaceuticals on the structuring of the take-private of Y-mAb Therapeutics Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQVmd2TFVpdF9LcEJ2b2ZuLTBjWU5nd1R0OHdvYlFLM0IxTjNiY3dXZVBMcEhCNmxubWk2c2pGS05MUk13NDA0ZTNzWUEwRzJ3Qm9Ic256ZzRnOVV5Zk5oUkUxM284Vk1jQTNScFlRQ1F5R1pJWjN6dzJ5TENDaHdfWU1LU1c5SDRJNTBwWjVaekRWZ2xDcGc?oc=5","date":"2025-08-06","type":"deal","source":"Pharmaceutical Executive","summary":"SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for $412 Million - Pharmaceutical Executive","headline":"SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for $412 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE5nd0puSl9EaUwyYkQ4bE9BSHZ0Z3dCdTZnSVhkMlMtTXNnLXhCRnM4Qm4telFEdzZUSThPZ2sxRXp0c2xmMjdKdG9KQlpsVm5zT2ItZS1yLTBGSVJkRmt0WlVYTUFFY1RTZzBZ?oc=5","date":"2025-08-06","type":"trial","source":"Oncology Pipeline","summary":"Y-Mabs falls to Serb | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Y-Mabs falls to Serb | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPY1FTVVYtdF9vYnZ4VHF1WUFSaDA1M2tGMGNmNlYwbG5yS2lVMFFNclZRS3N0WXBTQS1YLVZLWlVFUHc0R01YTEVQQWJPRFE1Y3ZycWhuSm1IZ21VRHVYRTJITlZmeVpiREJveHk5QVcybHBUYy14UjU1ZUt5SHllYTdVWVQyRUxxTkFrNl9wQk81ekhleXk3MjFR?oc=5","date":"2025-08-05","type":"pipeline","source":"Fierce Pharma","summary":"Y-mAbs signs off on $412M sale to SERB Pharmaceuticals, sending shares up 100% - Fierce Pharma","headline":"Y-mAbs signs off on $412M sale to SERB Pharmaceuticals, sending shares up 100%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFA2bmdrOFVodHQ0a29KYms3b1hZcWJPUlMwOEkxanFQbnZuSmpXY0dPRE1CQ3RncnhLcFhpZy10SFVrX3hTeUNkbFphdThrRkVCcVNN?oc=5","date":"2025-08-05","type":"deal","source":"FirstWord Pharma","summary":"Y-mAbs strategic review culminates in buyout by SERB Pharma - FirstWord Pharma","headline":"Y-mAbs strategic review culminates in buyout by SERB Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQTWRqX2dXOGVhYzRWM2pITTZabVg1T0E1UlppUkZpQnJ3UkotOFZ4Vl9STjAyUTJ5aEtYVG54a3ZrRjlPOGxfUDB3MVkxR1JlSFU0cVNYM18zUlJ2a0g5MTRNYWlFUk9CNG9BR1BUbk5VZzdGTEdKRnBpRWt5Q3ZQVWZMeC1MWEFmOE9xeEVTT1hPUEthTUhjZzZQaHJCemVIM3Vv?oc=5","date":"2025-08-05","type":"deal","source":"Stock Titan","summary":"$412M Acquisition: SERB Pharmaceuticals Buys Cancer Drug Maker Y-mAbs at 105% Premium - Stock Titan","headline":"$412M Acquisition: SERB Pharmaceuticals Buys Cancer Drug Maker Y-mAbs at 105% Premium","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNTS1HOHpTZVBNQ1R4ajRtQi1UbmJvWkVwVUJSS1ZwRTdibDBTcnhBM1lKY09XMkJsQW9MR0dsbHQzc1ZYTGNSa3hIaERBWHZxUjYyLU54b0lVaU12aThMcTJYVXo2alV4Q3oxQ1hIMldoVm92MjByWFBBSUY4ekJyb19Hc1U3b3ZsbUdXanJMcVZqUmllbVp6bENBWmlNSW8yTE91RjRrWXhvejdEMXoxMjh2X2RLRXVlSUFuZzJJLWp2MVZOR1lZ?oc=5","date":"2025-08-05","type":"pipeline","source":"Investing.com","summary":"Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition - Investing.com","headline":"Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":87685000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":87685000,"period":"2024-12-31"},{"value":84819000,"period":"2023-12-31"},{"value":84819000,"period":"2023-12-31"},{"value":65267000,"period":"2022-12-31"},{"value":65267000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":48990000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-29666000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":119904000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}